|Year : 2015 | Volume
| Issue : 2 | Page : 230-231
Cycloserine induced psychosis with hepatic dysfunction
Vishal R Tandon1, Neelam Rani1, Roshi1, Rahul Gupta2, Manu Arora3, Vijay Khajuria1, Vivek Mahajan1
1 Department of Pharmacology and Therapeutics, Government Medical College, Jammu, Jammu and Kashmir, India
2 Department of Pulmonary Medicine, Government Medical College, Jammu, Jammu and Kashmir, India
3 Department of Psychiatry, Government Medical College, Jammu, Jammu and Kashmir, India
|Date of Submission||05-Aug-2014|
|Date of Decision||25-Nov-2014|
|Date of Acceptance||11-Feb-2015|
|Date of Web Publication||17-Mar-2015|
Vishal R Tandon
Department of Pharmacology and Therapeutics, Government Medical College, Jammu, Jammu and Kashmir
Source of Support: IPC, Gaziabad (PvPI), Conflict of Interest: None
With the increase in the cases of multidrug resistance tuberculosis, second line anti-tubercular drugs like the cycloserine are being prescribed frequently. Isoniazid and ethambutol are reported to cause psychosis like state; however, few reports of cycloserine induced psychosis are available. To the best of our knowledge, this is the first case of cycloserine induced psychosis with hepatic dysfunction.
Keywords: Anti-tubercular treatment, cycloserine, multidrug resistant tuberculosis, psychosis
|How to cite this article:|
Tandon VR, Rani N, Roshi, Gupta R, Arora M, Khajuria V, Mahajan V. Cycloserine induced psychosis with hepatic dysfunction. Indian J Pharmacol 2015;47:230-1
|How to cite this URL:|
Tandon VR, Rani N, Roshi, Gupta R, Arora M, Khajuria V, Mahajan V. Cycloserine induced psychosis with hepatic dysfunction. Indian J Pharmacol [serial online] 2015 [cited 2022 Aug 18];47:230-1. Available from: https://www.ijp-online.com/text.asp?2015/47/2/230/153439
| » Introduction|| |
Cycloserine (D-4-amino-3-isoxazolidine) is a broad spectrum antibiotic produced by streptomyces-orchidaceus and is commonly used as a second line anti-tubercular treatment (ATT) in multidrug tuberculosis (MDR-TB). ATT induced psychosis is reported with drugs like isoniazid (INH) and ethambutol (EB). , Few reports of cycloserine induced psychiatric disorders like delusions and hallucinations, mania and associated seizures are available. ,,
With the emergence of MDR-TB and extensively drug-resistant TB, second line drugs like the cycloserine are used more frequently. We report a case of cycloserine induced psychosis with hepatic dysfunction.
| » Case Report|| |
A 45-year-old male patient weighing 60 kg, with sputum positive pulmonary Koch's was put on directly observed treatment (DOTs) Category-I as per revised national TB control programme guidelines on May 2012. On completion of extensive phase of the treatment patient remained acid fast bacilli (AFB) positive. Patient was labeled as Category-I failure and was prescribed Category-II treatment. Patient did not respond to this regimen too. Sputum culture for AFB and drug sensitivity showed the patient to be resistant to INH, rifampicin, streptomycin and EB. At this point of time, liver functions and all basic biochemical parameters were within normal limits. Hence, it was decided to change the treatment to DOTs Category-IV in December 2012, which included injection. Kanamycin 0.5 g intramuscular once daily 6 days a week, tablet levofloxacin 500 once daily, tablet ethionamide 500 mg once daily, tablet cycloserine 500 mg once daily, tablet pyrazinamide 1250 mg in daily divided doses and tablet pyridoxine 100 mg once daily.
In July 2014, the patient manifested with change in his behavior with aggression, violence with wife and other family members, anxiety, restlessness, irrelevant talking, insomnia, recent loss of interest in work, family, clothes and food; for which psychiatric consultation was sought.
The Hamilton score was 18 and brief psychotic rating score was 33 on 3 rd day. There were no signs of neurological deficiency.
Cycloserine was suspected as the possible offending agent for the adverse event. Thus, DOTS Category-IV regimen was de-challenged on July 2014. The patient was hospitalized and prescribed antipsychotic drugs like injection lorazepam 2 mg at bed time and as and when required, injection haloperidol 5 mg intramuscular twice daily, injection promethazine 50 mg intramuscular once daily, tablet olanzapine 10 mg twice daily, tablet nitrazepam 10 mg twice daily, tablet thiamine 100 mg 3 times a day. After brief de-challenge of 3 days and co-prescribed anti-psychotic medicine, most of the symptoms subsided and the patient improved within 4 days. Keeping this in view, cycloserine containing regimen was again started after 4 days. On 3 rd day of taking cycloserine patient again exhibited similar change in behavior. DOTS Category-IV regimen was stopped and the patient was put on the tablet. Levofloxacin 500 once daily, tablet macrozide 750 mg once daily and tablet pyridoxine 100 mg once daily. Antipsychotic drugs were continued.
The patient had no history of smoking, alcohol or drug abuse. There was no associated pathology or history of concurrent drug intake. He had no family history of mental disorders. Only recent disinterest in work, family, food, clothes was reported by attendants related to present adverse event. No history of anxiety or any conflict with family friends or at work place was reported. Clinical examination revealed that patient was well oriented to time, place and person, having normal pulse rate, icterus positive with, no palpable lymphodenopathy; blood pressure was 128/88 mmHg, chest examination showed bilateral decreased air entry with wheeze, cardiovascular examination was normal, abdomen and central nervous system (CNS) examination were also normal.
Laboratory investigations showed: Sputum AFB positive, hemoglobin 8.2 g/dL, total leukocyte count-18000 cu 3 mm, differential leukocyte count polymporphs - 78; eosinophils - 2 monocytes - 2 ; lymphocytes - 18 , blood sugar fasting - 80 mg/dL, thyroid profile-normal, erythrocyte sedimentation rate - 42 mm/h, serum urea - 23 mg/dL, serum creatinine - 0.5 mg/dL, HIV - I and II-nonreactive, serum bilirubin - 5.4 mg/dL, aspirate transferase - 192 mg/dL, alanine transferase 202 mg/dL, Vitamin B 6 levels were normal, serum. electrolytes were within normal limits. X-ray (PA view) showed bilateral fibrotic lesions in upper zones, ultrasonography abdomen and computed tomography scan head were normal.
| » Discussion|| |
The temporal relationship, the fact that brief de-challenge ameliorated the symptoms and re-challenge of cycloserine further aggravated the psychosis suggests that cyclosrine was the suspected drug for the adverse drug event. Furthermore, the appearance of psychiatric manifestations could not be explained by any concurrent disease, drug or chemical. Adverse drug reaction (ADR) was probable as assessed by WHO uppasla monitoring the center causality scale and Naranjo's score (score = 8). ,
Severity of the reaction as assessed using Hartwig ADR severity assessment scale  classified the said ADR as potentially serious. Preventability assessment was done by using Schumock and Thornton scale  which classified the ADRs as preventable. The ADR was not studied for dose dependent response and in view of its uncertain mechanism it is difficult to comment on the type of ADR.
Sharma et al.  reported psychosis, delusions and hallucinations with cycloserine. While, mania was the main presentation reported by Bakhla et al.  and seizure with psychosis in the case reported by Fujita et al.  Unlike above cases our patient was aggressive, violent, restlessness, anxious and presented with insomnia and had severe hepatic dysfunction.
The exact mechanism of such ADR is uncertain. However, possible modulation of N-methyl-D-aspartate receptor (NMDAR) antagonists and partial agonist at NMDAR associated glycine site by the drug as proposed by Bakhla et al.  may be the possible mechanism, in this case. The current case further supports this hypothesis since aggression and insomnia suggests a CNS stimulant action of the drug although no seizures were observed in our patient.
Another interesting possibility remains that deranged liver function in our case may have contributed to the decreased metabolism of the drug and hence the response. However, this remains the constraint as drug levels could not be assessed.
The current case report highlights that the psychiatric evaluation should be done preferably before and after prescribing cycloserine containing MDR regimens so that such potentially serious reactions can be prevented before any permanent damage is done.
| » References|| |
Prasad R, Garg R, Verma SK. Isoniazid- and ethambutol-induced psychosis. Ann Thorac Med 2008;3:149-51.
Behera C, Krishna K, Singh HR. Antitubercular drug-induced violent suicide of a hospitalised patient. BMJ Case Rep 2014;2014;bcr2013201469. doi: 10.1136/bcr-2013-201469.
Sharma B, Handa R, Nagpal K, Prakash S, Gupta PK, Agrawal R. Cycloserine-induced psychosis in a young female with drug-resistant tuberculosis. Gen Hosp Psychiatry 2014;36:451.e3-4.
Bakhla AK, Gore PS, Srivastava SL. Cycloserine induced mania. Ind Psychiatry J 2013;22:69-70.
Fujita J, Sunada K, Hayashi H, Hayashihara K, Saito T. A case of multi-drug resistant tuberculosis showing psychiatric adverse effect by cycloserine. Kekkaku 2008;83:21-5.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al.
A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 2000;356:1255-9.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32.
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992;27:538.
|This article has been cited by|
||Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis
| ||Wael A. Alghamdi, Abdullah Alsultan, Mohammad H. Al-Shaer, Guohua An, Shahriar Ahmed, Yosra Alkabab, Sayera Banu, Ketevan Barbakadze, Eric Houpt, Maia Kipiani, Lali Mikiashvili, Stephan Schmidt, Scott K. Heysell, Russell R. Kempker, J. Peter Cegielski, Charles A. Peloquin |
| ||Antimicrobial Agents and Chemotherapy. 2019; 63(5) |
|[Pubmed] | [DOI]|
||Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon
| ||Zubair Shanib Bhat, Muzafar Ahmad Rather, Mubashir Maqbool, Zahoor Ahmad |
| ||Biomedicine & Pharmacotherapy. 2018; 103: 1733 |
|[Pubmed] | [DOI]|